Theravance Biopharma, Inc.
NASDAQ:TBPHBiotechnology
-$0.07 today
- Market cap
- $882.64M
- Beta
- 0.18
- P/E (TTM)
- 7.4
- EPS (TTM)
- $2.23
Volume 10.02M
Average 0.43M
TBPH Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Theravance Biopharma, Inc.NASDAQ: TBPH
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $4.5M fell 7.6% year over year, ahead of the -14.0% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 0.5% from the prior quarter. Over 3 fiscal years it compounded at -22.5% a year.
Context
- Stock-based compensation amounted to 17.2% of revenue in FY2025, down 16.0 pp from a year earlier.
- Stock-based compensation increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -7.6% holds above the trailing-twelve-month pace of -14.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 18.48M USD
- Year-over-year change
- -13.6%
- 4-year CAGR
- -26.1%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.48M | -13.6% |
| FY2024 | 2024-12-31 | 21.39M | -15.7% |
| FY2023 | 2023-12-31 | 25.37M | -36.1% |
| FY2022 | 2022-12-31 | 39.73M | -36.0% |
| FY2021 | 2021-12-31 | 62.06M | — |
Stock-Based Compensation vs competitors
How TBPH compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -14.0% is the 7th highest of 8, against a peer median of +17.1%.
- Stock-based compensation amounts to 16.5% of revenue for TBPH, versus a peer median of 45.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $35.01M USD | +17.1% | -21.7% | 53.5% | |
| LTM Dec 2025 | $32.43M USD | -6.5% | +13.1% | — | |
| LTM Mar 2026 | $29.43M USD | +17.2% | +38.3% | — | |
| LTM Mar 2026 | $19.52M USD | +5.2% | +17.4% | 45.4% | |
| LTM Mar 2026 | $18.1M USD | -14.0% | -22.5% | 16.5% | |
| LTM Mar 2026 | $15.73M USD | +224.1% | +209.1% | — | |
| LTM Mar 2026 | $11.73M USD | -65.3% | -77.8% | 6.0% | |
| LTM Mar 2026 | $9.99M USD | +25.3% | — | 47.6% | |
| LTM Mar 2026 | €0 EUR | — | — | 0.0% | |
| Peer median (excluding TBPH) | — | +17.1% | +15.2% | 45.4% | |
Competitors are the stored peer set for TBPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (265.07M) | (92.82M) | (55.19M) | (56.42M) | 105.9M |
| Depreciation & Amortization | 8.6M | 7.02M | 4.26M | 3.62M | 5.64M |
| Deferred Income Tax | 0 | 0 | 3.21M | (7.57M) | (11.52M) |
| Stock-Based Compensation | 62.06M | 39.73M | 25.37M | 21.39M | 18.48M |
| Change in Working Capital | (39.55M) | 42.35M | (8.34M) | 20.36M | 120.47M |
| Accounts Receivables | 1.8M | (2.72M) | (689K) | (966K) | (27.1M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (3.53M) | (1.61M) | 6K | 750K | 326K |
| Other Working Capital | (37.82M) | 46.68M | (7.66M) | 20.57M | 147.24M |
| Other Non-Cash Items | 26.1M | (183.28M) | 3.7M | 7.09M | (423K) |
| Operating Cash Flow | (207.86M) | (186.99M) | (27M) | (11.54M) | 238.54M |
| Capital Expenditures | (3.41M) | (572K) | (2.49M) | (332K) | (42K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (158.31M) | (103.15M) | (134.53M) | (143.04M) | (248.22M) |
| Sales of Investments | 286.2M | 158.02M | 102.81M | 155.65M | 142.98M |
| Other Investing Activities | 6K | 1.1B | 1.51M | 0 | 0 |
| Investing Cash Flow | 124.49M | 1.15B | (32.7M) | 12.28M | (105.28M) |
| Debt Repayment | (10.73M) | (631.6M) | 0 | 0 | 0 |
| Common Stock Issued | 108.18M | 0 | 0 | 99K | 786K |
| Common Stock Repurchased | (9.06M) | (132.28M) | (199.55M) | (3.1M) | (4.03M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.47M | 5.08M | 618K | 508K | 0 |
| Financing Cash Flow | 91.86M | (758.81M) | (198.93M) | (2.5M) | (3.25M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 8.5M | 208.21M | (258.63M) | (1.75M) | 130.01M |
| Free Cash Flow | (211.26M) | (187.56M) | (29.49M) | (11.87M) | 238.5M |
Theravance Biopharma, Inc.
NASDAQ:TBPH
Intrinsic Alpha fair value
Locked
Current Price
$17.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.